Form 4: Crinetics Pharmaceuticals Executive Stephen F. Betz Sells 3,000 Shares

Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on May 10, 2024, at a price of $49.43 per share.

Summary

• On May 10, 2024, Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of the company's common stock.
• The sale was executed at a price of $49.43 per share.
• Following the transaction, Betz directly owns 89,643 shares of Crinetics Pharmaceuticals.
• The sale was conducted automatically under a pre-arranged Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing regarding an insider stock sale. The sale was conducted under a pre-arranged 10b5-1 trading plan, which reduces the likelihood of it being driven by current sentiment about the company's prospects. Therefore, the sentiment is neutral.

Industry Context

Insider sales are a common occurrence and are often scrutinized by investors for insights into a company's prospects, although sales under 10b5-1 plans are less indicative of current sentiment.

Stakeholder Impact

• The sale of shares by a company executive may be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates